Hologic (HOLX) Stock; Trades Flat as CEO Exit and $18.3B Blackstone-TPG Buyout Nears Final Close

TLDRs;

• Hologic shares remained largely unchanged as investors priced in a near-complete $18.3B buyout deal.
• CEO Steve MacMillan is set to step down once Blackstone and TPG finalize the acquisition.
• Regulatory approvals are cleared, with the transaction expected to close within days.
• The $76 per share cash offer and CVR structure continue to anchor investor expectations.

Hologic (NASDAQ: HOLX) shares traded mostly flat in late-session activity as markets digested the final stages of its $18.3 billion acquisition by private equity firms Blackstone and TPG. The women’s health diagnostics company is now only steps away from completing one of the largest healthcare buyouts in recent years, with closing expected around April 7, 2026.

The deal, first announced in October and later approved by shareholders in February, has already cleared all major regulatory hurdles. With approvals in place, the transaction is now in its final execution phase, effectively signaling Hologic’s exit from public markets.

CEO Transition Marks End of Era

Alongside the buyout, Hologic confirmed that Chief Executive Steve MacMillan will step down once the transaction is finalized. MacMillan, who has led the company since 2013 and served as chairman since 2015, will conclude a tenure defined by expansion in diagnostics, surgical technologies, and pandemic-era demand shifts.

Hologic, Inc., HOLX

Company leadership is expected to announce a successor only after the deal closes, as Hologic transitions from a publicly traded med-tech leader into a privately held portfolio asset under Blackstone and TPG. The leadership change marks the end of a decade-long transformation period that saw the company strengthen its position in women’s health diagnostics globally.

Investor Pricing Anchored at $76

Market pricing has remained tightly aligned with the acquisition terms, with Hologic last trading near $76.01 per share. That level closely mirrors the cash component of the offer, signaling strong investor confidence that the deal will close as expected.

Under the agreement, shareholders will receive $76 per share in cash, along with a contingent value right (CVR) that could add up to $3 per share if Hologic’s Breast Health division meets specified revenue targets in fiscal years 2026 and 2027. While the CVR introduces some uncertainty, it has not significantly shifted trading behavior, as most of the valuation is already reflected in the cash offer.

Final Trading Window Narrows

Nasdaq has indicated that April 6 is expected to be the last trading day for Hologic shares, with trading halted shortly after the closing auction. If the merger proceeds on schedule, shares will remain suspended on April 7 and be fully removed from listing on April 8.

The market structure leaves little room for volatility, as investors largely view the outcome as already priced in. The narrow spread between trading value and the deal price reflects a high level of confidence that no major obstacles remain.

Mixed Performance Across Business Segments

Despite the acquisition momentum, Hologic’s underlying business continues to show uneven performance. The company recently reported quarterly revenue of $1.05 billion, representing 2.5% year-over-year growth.

Growth was driven primarily by an 8.7% increase in surgical sales, while molecular diagnostics declined 3.5% due to weaker demand for COVID-related testing and aging STI assay products. This divergence highlights ongoing challenges within parts of the diagnostics portfolio even as other segments expand steadily.

Competitors such as Roche Diagnostics and Abbott Laboratories continue to exert pressure in molecular testing markets, an area that has become increasingly competitive as pandemic-driven demand normalizes.

The post Hologic (HOLX) Stock; Trades Flat as CEO Exit and $18.3B Blackstone-TPG Buyout Nears Final Close appeared first on CoinCentral.